MedTrace Logo

Postmenopausal Women,Treatment of Sleep Apnea and Co-morbidities

NCT01472315 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 34

Last updated 2013-03-11

No results posted yet for this study

Summary

The purposes of this study are to evaluate the degree and duration of medroxyprogesterone acetate effect as well as tolerability in postmenopausal women with nasal continuous positive airway pressure (CPAP) treated sleep apnea and to compare the effects with nasal CPAP.

Conditions

Interventions

DRUG

medroxyprogesterone acetate

MPA hormone therapy 30mg two hours before bedtime and 30mg right before going to bed every night for two weeks period

DRUG

Placebo

Placebo pills were taken in same way as active comparator

Sponsors & Collaborators

  • Turku University Hospital

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
42 Years
Max Age
77 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-01-31
Primary Completion
2000-11-30
Completion
2000-11-30

Countries

  • Finland

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01472315 on ClinicalTrials.gov